Partillion Nanovials to Support $2.5M CIRM-Funded Study of CAR T Cell Potency

By ACCESS Newswire

LOS ANGELES, CA / ACCESS Newswire / October 14, 2026 / Partillion Bioscience today announced that its Nanovial technology will be used in a USC-led research project supported by a $2.5 million California Institute for Regenerative Medicine (CIRM) Discovery Award. The project is led by Mohamed Abou-el-Enein, M.D., Ph.D., of the USC Keck School of Medicine.

CAR T therapies have transformed treatment for several blood cancers and are increasingly being investigated for autoimmune disease. Yet therapeutic responses can vary, and standard measurements do not always capture the functional differences between individual CAR T cells. By combining high-dimensional flow cytometry with Nanovial-based Cell-Cell-seq, the researchers aim to understand why some CAR T interactions produce effective responses while others fail.

"This project gives us the opportunity to go one level deeper, to the individual CAR T cell and the moment it encounters its target," said Mohamed Abou-el-Enein, M.D., Ph.D. "By bringing these different layers of information together, we aim to build a CAR T-cell atlas that could provide new insights into potency, failure and persistence, and inform the development of more consistent and durable cell therapies."

The project builds on prior Cell-Cell-seq research using Nanovials to study defined interactions between immune and tumor cells and connect those interactions with changes in gene expression. The CIRM-funded study will extend this approach to patient-derived samples through the Community Care Center of Excellence at Loma Linda University.

"We see cell-cell interactions as an important next frontier for functional cell analysis because they capture biology that is difficult to understand by studying cells in isolation," said Joseph de Rutte, Ph.D., CEO and co-founder of Partillion Bioscience. "Our goal is to make it possible to study these interactions at scale and ultimately make them a routine part of therapeutic development. This work shows how Nanovials can help bring that type of functional information into increasingly complex therapeutic research.

About Partillion Bioscience

Partillion Bioscience is pioneering a functional cell analysis platform built on its award-winning Nanovial technology. The company enables pharmaceutical and biotech partners to accelerate therapeutic development by screening millions of live cells in parallel, capturing critical functional outputs such as secretion, signaling, and viability.

Partillion's technology has been featured in Nature Nanotechnology, Nature Communications, Nature Protocols, PNAS, Science Advances, and ACS Nano, and recognized with the 2020 SLAS Innovation Award, 2022 SLAS New Product Award, and 2025 CYTO Innovation & Technology Showcase Award.

Learn more at www.partillion.com or contact info@partillion.com.

SOURCE: Partillion Bioscience



View the original press release on ACCESS Newswire

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.